in vivo cell therapy

BMS builds in ‘in vivo’ cell therapy with $1.5bn Orbital buy

DRRA8 hours ago04 mins

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is developing RNA medicines that can ‘reprogramme’ immune cells in the body and direct them to treat diseases. Its pipeline is headed by OTX-201,…

Umoja’s in vivo cell therapy fast-tracked by FDA

DRRA1 week ago05 mins

One of the pioneers of in vivo cell therapy, Umoja Biopharma, has cleared another regulatory milestone after getting a fast-track designation from the FDA for its lead candidate for blood cancers, partnered with AbbVie. The US regulator has awarded the status to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following two or…

Why Your Lipstick Might Be Making You S

SightGlass DOT slows pediatric myopia in Canadian population

AstraZeneca is Next to Reach MFN Deal with White House

Ypsomed Announces New U.S.-Based Manufacturing Site in North Carolina

How to get hair dye off skin ?

Trump administration moves to fire HHS employees amid shutdown

in vivo cell therapy

BMS builds in ‘in vivo’ cell therapy with $1.5bn Orbital buy

Umoja’s in vivo cell therapy fast-tracked by FDA